Relation of NT-probnp levels and cardiovascular disease risk factors in lean women with polycystic ovary syndrome

References

• Carmina E, Lobo RA. 1999. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. The Journal of Clinical Endocrinology & Metabolism 84:1897–1899.
   PubMed Web of Science ®Google Scholar
• Celik O, Sahin I, Celik N, Hascalik S, Keskin L, Ozcan H, et al. 2007. Diagnostic potential of serum N-terminal pro-B-type brain natriuretic peptide level in detection of cardiac wall stress in women with polycystic ovary syndrome: a cross-sectional comparison study. Human Reproduction 22:2992–2998.
   PubMed Web of Science ®Google Scholar
• Cho LW, Randeva HS, Atkin SL. 2007. Cardiometabolic aspects of polycystic ovarian syndrome. Vascular Health and Risk Management 3:55.
   PubMedGoogle Scholar
• Christakou C, Diamanti-Kandarakis E. 2013. Structural, biochemical and non-traditional cardiovascular risk markers in PCOS. Current Pharmaceutical Design 19:5764–5774.
   PubMed Web of Science ®Google Scholar
• Conway GS, Agrawal R, Betteridge D, Jacobs H. 1992. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clinical Endocrinology 37:119–125.
   PubMed Web of Science ®Google Scholar
• Coviello AD, Legro RS, Dunaif A. 2006. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. The Journal of Clinical Endocrinology & Metabolism 91:492–497.
   PubMed Web of Science ®Google Scholar
• Dawood A, Alkafrawy N, Saleh S, Noreldin R, Zewain S. 2018. The relationship between IL-18 and atherosclerotic cardiovascular risk in Egyptian lean women with polycystic ovary syndrome. Gynecological Endocrinology 34:294–297.
   PubMed Web of Science ®Google Scholar
• De Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, Mccabe CH, et al. 2001. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. New England Journal of Medicine 345:1014–1021.
   PubMed Web of Science ®Google Scholar
• Deveer R, Engin-Üstün Y, Uysal S, Su FA, Sarıaslan S, Gülerman C, Mollamahmutoğlu L. 2012. Serum brain natriuretic peptide and C-reactive protein levels in adolescent with polycystic ovary syndrome. Gynecological Endocrinology 28:602–605.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Dunaif A. 2012. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocrine Reviews 33:981–1030.
   PubMed Web of Science ®Google Scholar
• Dunaif A, Book CB. 1997. Insulin resistance in the polycystic ovary syndrome. Clinical Research in Diabetes and Obesity 15:249–274.
   Google Scholar
• Dunaif A, Segal KR, Futterweit W, Dobrjansky A. 1989. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38:1165–1174.
   PubMed Web of Science ®Google Scholar
• Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T. 1992. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 41:1257–1266.
   PubMed Web of Science ®Google Scholar
• Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. 1999. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22:141–146.
   PubMed Web of Science ®Google Scholar
• Gateva A, Kamenov Z, Tsakova A. 2013. NT-proBNP levels in premenopausal women with polycystic ovarian syndrome and/or obesity. Journal of Obstetrics and Gynaecology 33:868–872.
   Web of Science ®Google Scholar
• Goodarzi MO, Erickson S, Port SC, Jennrich RI, Korenman SG. 2003. Relative impact of insulin resistance and obesity on cardiovascular risk factors in polycystic ovary syndrome. Metabolism 52:713–719.
   PubMed Web of Science ®Google Scholar
• Jones H, Sprung VS, Pugh CJ, Daousi C, Irwin A, Aziz N, et al. 2012. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. The Journal of Clinical Endocrinology & Metabolism 97:3709–3716.
   PubMed Web of Science ®Google Scholar
• Kim JJ, Choi YM. 2013. Dyslipidemia in women with polycystic ovary syndrome. Obstetrics & Gynecology Science 56:137.
   PubMedGoogle Scholar
• Kurdoglu Z, Ozkol H, Tuluce Y, Koyuncu I. 2012. Oxidative status and its relation with insulin resistance in young non-obese women with polycystic ovary syndrome. Journal of Endocrinological Investigation 35:317–321.
   PubMed Web of Science ®Google Scholar
• Laughlin GA, Goodell V, Barrett-Connor E. 2010. Extremes of endogenous testosterone are associated with increased risk of incident coronary events in older women. The Journal of Clinical Endocrinology & Metabolism 95:740–747.
   PubMed Web of Science ®Google Scholar
• Legro RS, Kunselman AR, Dunaif A. 2001. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. The American Journal of Medicine 111:607–613.
   PubMed Web of Science ®Google Scholar
• Mather KJ, Kwan F, Corenblum B. 2000. Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity. Fertility and Sterility 73:150–156.
   PubMed Web of Science ®Google Scholar
• Matsuda M, Defronzo RA. 1999. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462–1470.
   PubMed Web of Science ®Google Scholar
• Meyer C, Mcgrath B, Teede H. 2005. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. The Journal of Clinical Endocrinology & Metabolism 90:5711–5716.
   PubMed Web of Science ®Google Scholar
• Morales A, Laughlin G, Bützow T, Maheshwari H, Baumann G, Yen S. 1996. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. The Journal of Clinical Endocrinology & Metabolism 81:2854–2864.
   PubMed Web of Science ®Google Scholar
• Olsen MH, Wachtell K, Tuxen C, Fossum E, Bang LE, Hall C, et al. 2004. N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study. Journal of Hypertension 22:1597–1604.
   PubMed Web of Science ®Google Scholar
• Omland TR, Aakvaag AR, Vik-Mo H. 1996. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. Heart 76:232–237.
   PubMed Web of Science ®Google Scholar
• Rizzo M, Berneis K, Hersberger M, Pepe I, Di Fede G, Rini GB, et al. 2009. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype. Human Reproduction 24:2286–2292.
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. 2004. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility 81:19.
   Web of Science ®Google Scholar
• Sampson M, Kong C, Patel A, Unwin R, Jacobs HS. 1996. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI‐1) activity in lean women with and without the polycystic ovary syndrome. Clinical Endocrinology 45:623–629.
   PubMed Web of Science ®Google Scholar
• Saxena P, Prakash A, Nigam A, Mishra A. 2012. Polycystic ovary syndrome: is obesity a sine qua non? A clinical, hormonal, and metabolic assessment in relation to body mass index. Indian Journal of Endocrinology and Metabolism 16:996.
   PubMedGoogle Scholar
• Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, et al. 2008. Withdrawn: postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health—National Heart, Lung, and Blood Institute Sponsored Women’s Ischemia Syndrome Evaluation. The Journal of Clinical Endocrinology & Metabolism 93:1276–1284.
   PubMed Web of Science ®Google Scholar
• Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, et al. 2010. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. The Journal of Clinical Endocrinology & Metabolism 95:2038–2049.
   PubMed Web of Science ®Google Scholar
• Wild RA, Grubb B, Hartz A, Van Nort JJ, Bachman W, Bartholomew M. 1990. Clinical signs of androgen excess as risk factors for coronary artery disease. Fertility and Sterility 54:255–259.
   PubMed Web of Science ®Google Scholar
• Yu C, Sanderson J, Shum I, Chan S, Yeung L, Hung Y, et al. 1996. Diastolic dysfunction and natriuretic peptides in systolic heart failure. Higher ANP and BNP levels are associated with the restrictive filling pattern. European Heart Journal 17:1694–1702.
   PubMed Web of Science ®Google Scholar